Signifier Medical Technologies Collaborates With Global Sleep Experts on Its Innovative Snoozeal® Device Clinical Trials

Signifier Medical Technologies today announced that it is partnering with twenty-seven Key Opinion Leaders in Sleep to test and build awareness around its Snoozeal® product in the lead up to its commercial launch. The company are innovators in the sleep-disordered breathing market

This research-focused initiative enhances Signifier Medical Technologies’ ability to fine-tune its revolutionary genioglossal muscle-neurostimulation technology and ensure that it meets the needs of patients around the world. It will also help refine internal commercial processes and ensure a seamless experience for future patients.

Key Opinion Leaders include top-tier physicians in key sleep therapeutic areas, including pulmonologists, cardiologists, neurologists and ear, nose and throat (ENT) specialists from leading health academies and institutions in North America, Europe and Australia. Signifier Medical Technologies is working with these medical professionals to build a large acceptance of the efficacy and the safety of this new technology and create a large multi-center clinical dataset that will further expand on the recent trials in Europe and United States.

Professor Atul Malhotra, Chief Investigator at the University of CaliforniaSan Diego for Snoozeal® mentioned the enthusiasm for having a new technology in this space. “I have been involved with the Snoozeal® device and have been doing ongoing research on this treatment. I am optimistic that this treatment will be an important treatment approach for patients with snoring and with mild sleep apnoea.”

“I have been very surprised by this device. The feedback and adherence from patients have been excellent, reporting an improvement in their snoring. The integration between the app and the device work is smooth, easy, and intuitive.” Dr. Peter M Baptista, MD, Ph.D. mentioned after using the device in some of his patients in Clínica Universidad de Navarra.

“We are pleased to work with professionals from some of the world’s top medical and academic institutions to revolutionize the sleep market,” said Prof Anshul Sama, co-founder, and CMO of Signifier Medical Technologies. “Our work together could impact the respiratory health of hundreds of millions of people and incorporates the latest and most innovative research in the field.”

These latest collaborations are an important step towards the global commercialization of Signifier Medical Technologies’ Snoozeal® product; currently commercially tested in the UK market.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.